Halberd Corporation CEO Letter - Seite 3
- Successfully eradicate the inflammatory cytokines, IL-6 and TNF-alpha, from Cerebral Spinal Fluid. These two cytokines are believed to be the principal causation of suicide ideation associated with PTSD.
- Presentations to the NFL, DARPA and the military outlining our achievements in elimination of the inflammatory cytokines believed to be associated with suicide ideation and PTSD and seek their support/endorsement/participation in and for our continuing study.
- Continue efforts to successfully eradicate other identified antigens and inflammatory cytokines associated with Alzheimer's Disease, Parkinson's Disease, etc.
- Continue to strengthen our Intellectual Property position through additional provisional patent applications and conversion of past provisional applications into patent applications and patents. NOTE_ Halberd Corporation has three existing patents and has filed eleven provisional patent applications to date. Our continuing strategy is to aggressively develop intellectual property.
- Continue to expand the number and breadth of scientific experts on Halberd's team to enhance our successes in the future.
SUMMARY
Halberd continues to strive to deliver maximum value to our shareholders by focusing on the prominent health issues not adequately addressed by other biomedical or pharmaceutical interests. Our
current focus on developing treatments for PTSD, CTE, and Alzheimer's Disease reflects that commitment. Since 9/11, four times as many military personnel have committed suicide than have been
killed in combat. Careers in contact sports have also produced alarming numbers of suicides associated with neurodegenerative diseases. Alzheimer's Disease is reportedly the seventh leading cause
of death in the US.
We believe that Halberd's scientists, using our technology and expertise, are equipped to develop successful treatments for these neurodegenerative diseases which plague our military, professional athletes and our people in general.
Sincerely,
William A. Hartman
Chairman, President & CEO
HALBERD CORPORATION
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC
Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the
exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.